e-learning
resources
Vienna 2012
Monday, 03.09.2012
Cell biology, blood and sputum biomarkers in airway diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison of serum osteopontin levels in patients with exacerbations and stable chronic obstructive pulmonary disease
Y. Cho, H. Kim, Y. Jeong, J. Lee, Y. Hwang (Jinju, Republic Of Korea)
Source:
Annual Congress 2012 - Cell biology, blood and sputum biomarkers in airway diseases
Session:
Cell biology, blood and sputum biomarkers in airway diseases
Session type:
Thematic Poster Session
Number:
2225
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Cho, H. Kim, Y. Jeong, J. Lee, Y. Hwang (Jinju, Republic Of Korea). Comparison of serum osteopontin levels in patients with exacerbations and stable chronic obstructive pulmonary disease. Eur Respir J 2012; 40: Suppl. 56, 2225
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
A 62-year-old man with scanty mucoid sputum
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Serum angiopoietin-2 levels in stable and exacerbated chronic obstructive pulmonary disease
Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema
Year: 2015
Serum magnesium levels of patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 22: Suppl. 45, 107s
Year: 2003
Serum leptin levels in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 259s
Year: 2002
Serum interferon-gamma levels in chronic obstructive pulmonary disease and asthma patients: correlation with respiratory parameters
Source: Eur Respir J 2001; 18: Suppl. 33, 75s
Year: 2001
Serum amyloid A in patients with stable chronic obstructive pulmonary disease
Source: International Congress 2018 – Clinical determinants and biomarkers of COPD
Year: 2018
High interleukin-33 is associated with acute exacerbation in patients with chronic obstructive pulmonary disease
Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases
Year: 2020
Periostin levels in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2018 – Biomarkers for evaluating COPD
Year: 2018
Changes in antioxidant enzyme levels in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2009 - Mechanisms of lung injury: COPD, asthma and acute lung injury
Year: 2009
A study of the level of interleukin-32 in induced sputum and plasma of patients with chronic obstructive pulmonary disease and asthma
Source: Annual Congress 2010 - Novel mechanisms in COPD
Year: 2010
Relationship between serum levels of testosterone and the severity of chronic obstructive pulmonary disease
Source: Virtual Congress 2020 – Investigations of COPD
Year: 2020
The levels of serum malonyldialhyde and paraoxonase in chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 24: Suppl. 48, 305s
Year: 2004
Comparison of blood eosinophils and plasma periostin in stable and non-stable chronic obstructive pulmonary disease: How we can improve the management of our patients
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Plasma fibrinogen in patients with chronic obstructive pulmonary disease (COPD) with or without secondary erythrocytosis
Source: Eur Respir J 2005; 26: Suppl. 49, 586s
Year: 2005
Simvastatin does not reduce levels of inflammatory blood markers in patients with stable chronic obstructive pulmonary disease
Source: Annual Congress 2008 - COPD
Year: 2008
Relationship between circulating thrombomodulin levels and latent progression of atherosclerosis in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Year: 2008
Increased urinary l-histidine in patients with asthma–chronic obstructive pulmonary disease overlap
Source: International Congress 2018 – Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS)
Year: 2018
IL-8 in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: Suppl. 33, 364s
Year: 2001
Association between serum YKL-40 and chronic obstructive pulmonary disease
Source: International Congress 2017 – COPD biomarkers
Year: 2017
Serum lysophosphatidic acid levels and exacerbation frequency in chronic obstructive pulmonary disease (COPD)
Source: Virtual Congress 2020 – Ageing, metabolic syndrome and the lung
Year: 2020
Variability in expression of aquoporine 1 in chronic obstructive pulmonary disease and interstitial lung disease patients
Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease?
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept